In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines.

2.50
Hdl Handle:
http://hdl.handle.net/2436/29507
Title:
In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines.
Authors:
Guo, X.; Evans, T.R.J.; Somanath, S.; Armesilla, Angel Luis; Darling, John L.; Schatzlein, A.; Cassidy, James; Wang, Weiguang
Abstract:
Nuclear factor-kappa B (NF-kappaB) is a transcription factor with high transcriptional activity in cancer cells. In this study, we developed a novel enhancer-promoter system, kappaB4-CEA205, in which the basal carcinoembryonic antigen (CEA) promoter sequence (CEA205) was placed downstream of the four tandem-linked NF-kappaB DNA-binding sites (kappaB4). In combination with a kappaB4 enhancer, the transcriptional activity of the CEA promoter was significantly enhanced (three- to eight-fold) in cancer cell lines but not in normal cells. In cancer cell lines, the transcriptional activity of kappaB4-CEA205 was comparable with that of the SV40 promoter. We also constructed vectors in which the thymidine phosphorylase (TP) cDNA was under the control of CEA205, kappaB4, kappaB4-CEA205 and CMV promoters, respectively. TP protein and enzyme activity were detected at comparable levels in kappaB4-CEA205- and CMV-driven TP cDNA-transfected cancer cell lines (H630 and RKO). The kappaB4-TP and CEA205-TP-transfected cell lines, respectively, only demonstrated negligible and low levels of TP protein and enzyme activity. Both CMV- and kappaB4-CEA205-driven TP cDNA transiently transfected cells were 8- to 10-fold sensitised to 5-fluorouracil (5-FU) prodrug, 5'-deoxy-5-fluorouradine (5'-DFUR), in contrast to only 1.5- to 2-fold sensitised by the kappaB4- and CEA205-driven TP cDNA-transfected cells. The bystander killing effect of CMV- and kappaB4-CEA205-driven TP cDNA-transfected cells was comparable. This is the first report that indicates that the NF-kappaB DNA-binding site could be used as a novel cancer-specific enhancer to improve cancer-specific promoter activity in gene-directed enzyme prodrug therapy.
Citation:
British Journal of Cancer, 97(6): 745-754
Publisher:
Nature Publishing Group
Journal:
British Journal of Cancer
Issue Date:
2007
URI:
http://hdl.handle.net/2436/29507
DOI:
10.1038/sj.bjc.6603930
PubMed ID:
17687334
Additional Links:
http://www.nature.com/bjc/journal/v97/n6/abs/6603930a.html
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
Cancer Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorGuo, X.-
dc.contributor.authorEvans, T.R.J.-
dc.contributor.authorSomanath, S.-
dc.contributor.authorArmesilla, Angel Luis-
dc.contributor.authorDarling, John L.-
dc.contributor.authorSchatzlein, A.-
dc.contributor.authorCassidy, James-
dc.contributor.authorWang, Weiguang-
dc.date.accessioned2008-06-04T13:16:58Z-
dc.date.available2008-06-04T13:16:58Z-
dc.date.issued2007-
dc.identifier.citationBritish Journal of Cancer, 97(6): 745-754en
dc.identifier.issn0007-0920-
dc.identifier.pmid17687334-
dc.identifier.doi10.1038/sj.bjc.6603930-
dc.identifier.urihttp://hdl.handle.net/2436/29507-
dc.description.abstractNuclear factor-kappa B (NF-kappaB) is a transcription factor with high transcriptional activity in cancer cells. In this study, we developed a novel enhancer-promoter system, kappaB4-CEA205, in which the basal carcinoembryonic antigen (CEA) promoter sequence (CEA205) was placed downstream of the four tandem-linked NF-kappaB DNA-binding sites (kappaB4). In combination with a kappaB4 enhancer, the transcriptional activity of the CEA promoter was significantly enhanced (three- to eight-fold) in cancer cell lines but not in normal cells. In cancer cell lines, the transcriptional activity of kappaB4-CEA205 was comparable with that of the SV40 promoter. We also constructed vectors in which the thymidine phosphorylase (TP) cDNA was under the control of CEA205, kappaB4, kappaB4-CEA205 and CMV promoters, respectively. TP protein and enzyme activity were detected at comparable levels in kappaB4-CEA205- and CMV-driven TP cDNA-transfected cancer cell lines (H630 and RKO). The kappaB4-TP and CEA205-TP-transfected cell lines, respectively, only demonstrated negligible and low levels of TP protein and enzyme activity. Both CMV- and kappaB4-CEA205-driven TP cDNA transiently transfected cells were 8- to 10-fold sensitised to 5-fluorouracil (5-FU) prodrug, 5'-deoxy-5-fluorouradine (5'-DFUR), in contrast to only 1.5- to 2-fold sensitised by the kappaB4- and CEA205-driven TP cDNA-transfected cells. The bystander killing effect of CMV- and kappaB4-CEA205-driven TP cDNA-transfected cells was comparable. This is the first report that indicates that the NF-kappaB DNA-binding site could be used as a novel cancer-specific enhancer to improve cancer-specific promoter activity in gene-directed enzyme prodrug therapy.en
dc.language.isoenen
dc.publisherNature Publishing Groupen
dc.relation.urlhttp://www.nature.com/bjc/journal/v97/n6/abs/6603930a.htmlen
dc.subjectNF-Ben
dc.subjectCEAen
dc.subjectGDEPTen
dc.subjectThymidine Phosphorylaseen
dc.subjectColorectal canceren
dc.subjectCancer, Colorectal-
dc.subject.meshBlotting, Westernen
dc.subject.meshCarcinoembryonic Antigenen
dc.subject.meshCell Line, Tumoren
dc.subject.meshColonic Neoplasmsen
dc.subject.meshColorectal Neoplasmsen
dc.subject.meshCytomegalovirusen
dc.subject.meshDNA, Complementaryen
dc.subject.meshFluorouracilen
dc.subject.meshGene Therapyen
dc.subject.meshHumansen
dc.subject.meshNF-kappa Ben
dc.subject.meshProdrugsen
dc.subject.meshPromoter Regions (Genetics)en
dc.subject.meshReverse Transcriptase Polymerase Chain Reactionen
dc.subject.meshThymidine Phosphorylaseen
dc.subject.meshTransfectionen
dc.titleIn vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines.en
dc.typeArticleen
dc.identifier.journalBritish Journal of Canceren
All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.